Old Web
English
Sign In
Acemap
>
authorDetail
>
Panos Xenopoulos
Panos Xenopoulos
University of Cambridge
Physical therapy
Medicine
Alemtuzumab
Incidence (epidemiology)
Expanded Disability Status Scale
3
Papers
315
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
2017
Neurology
Alasdair Coles
Jeffrey A. Cohen
Edward Fox
Gavin Giovannoni
Hans-Peter Hartung
Eva Havrdova
Sven Schippling
Krzysztof Selmaj
Anthony Traboulsee
D Alastair S Compston
David Margolin
Karthinathan Thangavelu
Mc Chirieac
Darlene Jody
Panos Xenopoulos
Richard J. Hogan
Michael Panzara
Douglas L. Arnold
Show All
Source
Cite
Save
Citations (169)
Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
2017
Neurology
Eva Havrdova
Douglas L. Arnold
Jeffrey A. Cohen
Hans-Peter Hartung
Edward Fox
Gavin Giovannoni
Sven Schippling
Krzysztof Selmaj
Anthony Traboulsee
D Alastair S Compston
David Margolin
Karthinathan Thangavelu
C. E. Rodriguez
Darlene Jody
Richard J. Hogan
Panos Xenopoulos
Michael Panzara
Alasdair Coles
Show All
Source
Cite
Save
Citations (139)
Alemtuzumab CARE-MS II 5-year follow-up
2017
Alasdair Coles
J. A. Cohen
Edward Fox
Gavin Giovannoni
H.-P. Hartung
Eva Havrdova
Sven Schippling
Krzysztof Selmaj
Anthony Traboulsee
A. Compston
David Margolin
Karthinathan Thangavelu
Mc Chirieac
Darlene Jody
Panos Xenopoulos
Richard J. Hogan
Michael Panzara
D.L. Arnold
Show All
Source
Cite
Save
Citations (7)
1